| 16.665 2.075 (14.22%) | 10-24 14:57 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.36 | 1-year : | 40.02 |
| Resists | First : | 25.99 | Second : | 34.27 |
| Pivot price | 15.14  |
|||
| Supports | First : | 12.61 | Second : | 10.49 |
| MAs | MA(5) : | 14.42 |
MA(20) : | 16.36  |
| MA(100) : | 14.63 |
MA(250) : | 14.03 |
|
| MACD | MACD : | -2 |
Signal : | -2 |
| %K %D | K(14,3) : | 31.2 |
D(3) : | 19 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 39.9 | Low : | 0.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SCLX ] has closed below upper band by 29.7%. Bollinger Bands are 16.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.91 - 14.99 | 14.99 - 15.07 |
| Low: | 13.46 - 13.57 | 13.57 - 13.66 |
| Close: | 14.43 - 14.59 | 14.59 - 14.73 |
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Tue, 07 Oct 2025
Scilex Holding appoints Stephen Ma as chief operating officer - Investing.com
Wed, 01 Oct 2025
Scilex Holding Company Enters Warrant Exercise Agreement - TipRanks
Wed, 01 Oct 2025
Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase - Yahoo Finance
Fri, 26 Sep 2025
Datavault AI Announces Closing of Initial Tranche Investment from Scilex Holding Company - Business Wire
Thu, 04 Sep 2025
Major Pharma Merger Advances: Semnur Pharmaceuticals-Denali Capital Deal Gets Shareholder Green Light - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 7 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 20.1 (%) |
| Held by Institutions | 73.3 (%) |
| Shares Short | 514 (K) |
| Shares Short P.Month | 533 (K) |
| EPS | -15.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -45.3 |
| Profit Margin | -179.2 % |
| Operating Margin | -206.3 % |
| Return on Assets (ttm) | -65.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -39.5 % |
| Gross Profit (p.s.) | 4.19 |
| Sales Per Share | 5.97 |
| EBITDA (p.s.) | -12.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 21 (M) |
| Levered Free Cash Flow | 112 (M) |
| PE Ratio | -1.07 |
| PEG Ratio | 0 |
| Price to Book value | -0.37 |
| Price to Sales | 2.76 |
| Price to Cash Flow | 5.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|